M
Maud Condomines
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 22
Citations - 2066
Maud Condomines is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 13, co-authored 21 publications receiving 1756 citations. Previous affiliations of Maud Condomines include Kettering University & University of Montpellier.
Papers
More filters
Journal ArticleDOI
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
TL;DR: Co-transduced T cells destroy tumors that express both antigens but do not affect tumors expressing either antigen alone, and this 'tumor-sensing' strategy may help broaden the applicability and avoid some of the side effects of targeted T-cell therapies.
Journal ArticleDOI
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao,Zeguo Zhao,Maud Condomines,Maud Condomines,Sjoukje J. C. van der Stegen,Sjoukje J. C. van der Stegen,Fabiana Perna,Fabiana Perna,Christopher C. Kloss,Christopher C. Kloss,Gertrude Gunset,Gertrude Gunset,Jason Plotkin,Jason Plotkin,Michel Sadelain,Michel Sadelain +15 more
TL;DR: In this article, the authors used an in vivo "stress test" to challenge CD19-targeted T cells, and studied the functionality and persistence imparted by seven different CAR structures providing CD28 and/or 4-1BB costimulation.
Journal ArticleDOI
Induction of angiogenesis by normal and malignant plasma cells.
Dirk Hose,Jérôme Moreaux,Tobias Meissner,Anja Seckinger,Hartmut Goldschmidt,Axel Benner,Karène Mahtouk,Jens Hillengass,Thierry Rème,John De Vos,Michael Hundemer,Maud Condomines,Uta Bertsch,Jean-François Rossi,Anna Jauch,Bernard Klein,Thomas Möhler +16 more
TL;DR: BMPCs express a surplus of proangiogenic over antiangiogenesis genes transmitting to the ability to induce in vitro angiogenesis, leading to bone marrow angiogenic at various degrees in all myeloma patients.
Journal ArticleDOI
Cancer/testis genes in multiple myeloma: Expression patterns and prognosis value determined by microarray analysis
Maud Condomines,Maud Condomines,Dirk Hose,Pierre Raynaud,Michael Hundemer,John De Vos,John De Vos,Marion Baudard,Thomas Moehler,Véronique Pantesco,Marion Moos,Jean-François Schved,Jean-François Rossi,Thierry Rème,Hartmut Goldschmidt,Bernard Klein,Bernard Klein +16 more
TL;DR: To assess the expression of CT genes on a pangenomic base in multiple myeloma (MM), to assess the prognosis value of CT gene expression, and to provide selection strategies for CT Ags in clinical vaccination trials, gene expression profiling is reported.
Proceedings ArticleDOI
Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma
TL;DR: The results demonstrate for the first time the impressive anti-tumor efficacy of a CD56 targeted chimeric antigen receptor in a systemic xenograft model of myeloma.